The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent?
Cyra Patel, Julia ML Brotherton, Alexis Pillsbury, Sanjay Jayasinghe, Basil Donovan, Kristine Macartney, Helen Marshall
Eurosurveillance | EUR CENTRE DIS PREVENTION & CONTROL | Published : 2018
BACKGROUND: A National human papilloma virus (HPV) Vaccination Programme for the prevention of HPV infection and associated disease using the quadrivalent HPV vaccine (4vHPV) has been funded and implemented in Australia since 2007, initially for girls only and extended to boys in 2013, with uptake rates among the highest observed worldwide. AIM: We report on the impact of this national programme on HPV prevalence and associated disease burden and estimate the potential impact of adopting a nonavalent HPV (9vHPV) vaccine. METHODS: We performed a non-systematic literature review of studies measuring the burden of HPV-associated disease and infection in Australia before and after introduction o..View full abstract
There was no specific funding for this study. The National Centre for Immunisation Research and Surveillance (NCIRS) receives support, either financial or otherwise, from the Australian Government Department of Health, New South Wales Department of Health, The Sydney Children's Hospital Network, and the University of Sydney, Australia. Helen Marshall and Basil Donovan acknowledge funding from NHMRC for Research Fellowships.